Business Wire

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Share

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.

Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.

Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.

In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.

During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.

In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.

“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”

Christophe Quéva, CEO of Egle Therapeutics

About Egle Therapeutics

Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.

Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.

For more information www.egle-tx.com

About France 2030

✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.

✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).

✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.

✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.

For more information: france2030.gouv.fr | @SGPI_avenir

About the Call for Projects “Innovations in Biotherapies and Bioproduction”

The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.

About Bpifrance

Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.

Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.

For more information: www.bpifrance.fr

View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/

Contacts

contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Winners of the Japanese Culinary Arts Award (JCAA) 2024-2025, Supported by JCDC, Chosen18.3.2025 14:00:00 EET | Press release

The finals were hard-fought, and included the participation of three foreigners who had won the European Qualifier, Asian Qualifier, and Foreigners Online Qualifier. On March 9, 2025, the finals of the Japanese Culinary Arts Award (JCAA) 2024-2025 were held at the Kyoto Culinary Art College, and Mr. Takuya Fujii of the Kyoto Culinary Art College took top place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313510455/en/ Awards Ceremony Three foreigners, Cristina Elena Muñoz Fernández (Spain), winner of the European Qualifier, Le Minh Tien (Vietnam), winner of the Asian Qualifier, and Jorge Ramos (Mexico), winner of the Foreigners Online Qualifier, also fought it out at the finals venue. Unfortunately, none of them won, but we want to show our respect to their hard efforts. The Japanese Culinary Arts Award 2024-2025 https://culinary-academy.jp/jpn/compe/en/index.html This championship celebrates the passion and skill in J

Corona Welcomes The World To Visit Its Tropical Paradise, Corona Island18.3.2025 14:00:00 EET | Press release

Today, Corona, the world’s most valuable beer brand1, officially opens the doors to Corona Island—an eco-protected natural paradise off the coast of Colombia, now available for booking on major travel platforms. Travelers worldwide can secure their stay directly at livecoronaisland.com or through Airbnb, Expedia, and Booking.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318968356/en/ Corona Island As a beer brewed with natural ingredients, Corona Island is symbolic of the brand’s dedication to live in harmony with nature. It is more than just a destination; it offers an experience that will inspire travelers to fall in love with the natural world and motivation to protect its resources. Originally debuting in 2021 as an invite-only getaway located 20 km (12 mi) southwest of Cartagena, and accessible only by boat, the island offers guests a chance to disconnect from daily life and reconnect with nature through curate

Andy Walsky of ExaGrid Recognized on the Prestigious 2025 CRN ® Channel Leaders Lists for APAC18.3.2025 14:00:00 EET | Press release

ExaGrid®, the industry’s only Tiered Backup Storage solution with Retention Time-Lock that includes a non-network-facing tier (creating a tiered air gap), delayed deletes and immutability for ransomware recovery, today announced that CRN®, a brand of The Channel Company, has named Andy Walsky, ExaGrid’s Vice President of EMEA & APAC Sales, to the highly-anticipated 2025 CRN® Channel Leaders list for the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318899549/en/ “I am honored to be named to this list, and grateful to CRN for its coverage of the APAC region,” said Andy Walsky. “Working with channel partners is the key to success for any company and must be treated with the highest priority. My channel philosophy is to treat the channel as you would want to be treated yourself, always be fair and keep your word. Developing trust with channel partners is critical—it takes time to build, but it can be quickly ru

Armis Appoints Patrick McCue to Senior Vice President of Global Partners18.3.2025 14:00:00 EET | Press release

Armis, the cyber exposure management & security company, today announced the appointment of Patrick McCue to Senior Vice President of Global Partners. In this role, McCue will expand partner engagement and increase partner-driven revenue and services, enabling joint customers to better manage their cyber risk exposure in real time. “Armis is deeply committed to our partners. The dynamic challenges security leaders face go beyond any one organization or entity, which is why we’re partner-first and focused on collaboration to advance the industry overall,” said Alex Mosher, President of Armis. “Patrick’s proven track record in successfully driving growth through strategic partnerships makes him the ideal leader to scale Armis’ partner ecosystem and bring even greater value to our partners and customers.” “I am eager to dive in and contribute to Armis’ exceptional momentum and ongoing success of its partner program,” said McCue. “The partner community plays a critical role in extending th

SBC Medical Group to Announce Full Year 2024 Financial Results on March 28, 202518.3.2025 13:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced that it will report its full year 2024 financial results before the U.S. market open on Friday, March 28, 2025. The Company will hold a conference call on Friday, March 28, 2025 at 8:00 am Eastern Time (or Friday, March 28, 2025 at 9:00 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. It will automatically direct you to the registration page of "SBC 2024 Full Year Financial Results Briefing". Please follow the steps to enter your registration details, then click "Submit". Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past inve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye